home / stock / agnpf / agnpf news

AGNPF News and Press, Algernon Pharmaceuticals Inc - Class A

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
AGNPF - Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
AGNPF - Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...

AGNPF - Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...

AGNPF - Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming speci...
AGNPF - Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it pl...

AGNPF - Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment

--News Direct-- Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was init...

AGNPF - News Alert: Algernon Pharmaceuticals: Trial Complete for COVID-19 Treatment

2024-03-27 17:08:02 ET Hopeful that lead compound will be found to reduce severity and duration of covid-19 infection Algernon Pharmaceuticals is a clinical stage drug repurposing company. On March 6th, 2020, the company announced that it was going to explore the potential of usin...
AGNPF - CEO Clips - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial

2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...

AGNPF - Algernon Pharmaceuticals: Next Phase Study of Ifenprodil for COVID-19

2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...

AGNPF - Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
Next 10